di·a·be·tol·o·gist /ˌdaɪəbɪˈtɒlədʒɪst/ Show Spelled[dahy-uh-bi-tol-uh-jist] Show IPA
–noun
a physician, usually an internist or endocrinologist, who specializes in the treatment of diabetes mellitus.
Origin:
1960–65; diabet(es) + -o- + -logy
Wednesday, April 28, 2010
Sunday, April 25, 2010
kids off school for the entire week.....
I had my neice this week monday thru friday for a minimum of 8 hours per day.....my neice tallia is a T1D.
I think that is the most time I have had her that many days in a row since she was diagnosed more than 2 years ago.
I am in awe of my sister and brother-in-law with how hard they must have to work to keep Tallia healthy. I did not have site changes or refilling insulin pump or all the other "stuff" that goes along with her care along with the worry and constant checking and monitoring ....it is exhausting.
Any parent caring for a child with a disease, illness,or handicap is a unbelievable caring and strong person. I salute you.
I think that is the most time I have had her that many days in a row since she was diagnosed more than 2 years ago.
I am in awe of my sister and brother-in-law with how hard they must have to work to keep Tallia healthy. I did not have site changes or refilling insulin pump or all the other "stuff" that goes along with her care along with the worry and constant checking and monitoring ....it is exhausting.
Sunday, April 18, 2010
New England Classic
New England Classic 150 & 550
Welcome to our Tour de Cure team page!
We are determined to reach our team goal one rider at a time.
Why Ride?
On behalf of the millions of Americans with diabetes and their families and friends, we are counting on you to help our team make a difference! The funds we raise will support the American Diabetes Association's important research, information and advocacy efforts and its mission: to prevent and cure diabetes and to improve the lives of all people affected by diabetes.
Join our Team!
If you choose to ride with us, you'll get to take part in a fun, exciting, healthy event for the whole family. You can even invite friends and family to join. Every rider counts, and everyone is welcome to join our team!
Support our Team!
Support our team by making a donation, riding or volunteering. We can't do it alone!
So let's get in gear and ride to Stop Diabetes!
Team Tally - Join Team Raised
Lynne Demond $35.00
Denotes a Team Captain
Team Tally
Goal:
$3,000.00
Achieved:
$35.00
http://main.diabetes.org/site/TR/TourdeCure/EasternNewEnglandArea?team_id=469808&pg=team&fr_id=6930&et=_YD0IxTATNNi0AvaOxATHQ..&s_tafId=306107
i have been tapped to sponsor a rider in the tour de cure...cant think of a better way to spend my money....
Dear Friend,
I have decided to join thousands of fellow riders from across the country in this year's Tour de Cure to raise money to help stop diabetes and further the mission of the American Diabetes Association: to prevent and cure diabetes and to improve the lives of all those affected by diabetes.
I am asking for your help. By making a donation on my behalf, you will be helping the American Diabetes Association change the future of diabetes by providing community-based education programs, protect the rights of people with diabetes and fund critical research for a cure.
As you may know, diabetes is a disease in which the body does not produce or properly use insulin. Insulin is a hormone that is needed to convert sugar, starches and other food into energy needed for daily life. Nearly 24 million Americans are living with diabetes. If current trends continue, one out of three children will face a future with diabetes. This is a startling statistic and your donation will help to change this.
I know my participation in this year's Tour de Cure can and will make a difference. Please help me reach my goal of <$600.00> by supporting me with a donation. You can follow the link below to my personal Web page to make a secure, 100% tax deductible donation. (If you do not want to donate online, please make your check payable to the American Diabetes Association and mail your contribution to me at Lynne Demond, 9 Grove Road, Natick Mass 01760.)
Together we will help stop diabetes.
Warm Regards,
Lynne
I have decided to join thousands of fellow riders from across the country in this year's Tour de Cure to raise money to help stop diabetes and further the mission of the American Diabetes Association: to prevent and cure diabetes and to improve the lives of all those affected by diabetes.
I am asking for your help. By making a donation on my behalf, you will be helping the American Diabetes Association change the future of diabetes by providing community-based education programs, protect the rights of people with diabetes and fund critical research for a cure.
As you may know, diabetes is a disease in which the body does not produce or properly use insulin. Insulin is a hormone that is needed to convert sugar, starches and other food into energy needed for daily life. Nearly 24 million Americans are living with diabetes. If current trends continue, one out of three children will face a future with diabetes. This is a startling statistic and your donation will help to change this.
I know my participation in this year's Tour de Cure can and will make a difference. Please help me reach my goal of <$600.00> by supporting me with a donation. You can follow the link below to my personal Web page to make a secure, 100% tax deductible donation. (If you do not want to donate online, please make your check payable to the American Diabetes Association and mail your contribution to me at Lynne Demond, 9 Grove Road, Natick Mass 01760.)
Together we will help stop diabetes.
Warm Regards,
Lynne
We met some Medtronic wonderful Representatives...
left to right- Donna Annese (designer of Tummietote by Tallygear, Tody Webster (rep for Medtronic) Bill Woods (publisher of 1happydiabetic), Doreen Merriam ( rep for Medtronic), Matthew Annese (CFO Tallygear), Tallia Annese ( model and inspiration of Tallygear)
1 happy diabetic
We had the pleasure of meeting Bill Woods from his well-known videos of 1 Happy Diabetic, we have been in contact with him for several months and was finally able to meet up with him at the Connecticut Expo Center in Hartford Ct. that was sponsored by the American Diabetes Association. He is just as happy in person and we thoroughly enjoyed talking to him....I was so excited that i asked him for his autograph!....we shared ideas , stories and some great information. We can't wait to see him at another event.
Tuesday, April 13, 2010
March 26, 2010 ...info just released...lets hope for spontaniety in the cells!
Some Pancreas Cells Have Potential to Spontaneously Change into Insulin-Producing Cells
We tend to regard the mature cells in our bodies as having reached their final destinations - if they become specialists, like heart or brain cells, they remain that way. But more and more, research is showing this is not always the case. And fortunately for people with type 1 diabetes, today's online issue of the journal Nature reports on similar transformational prospects for cells in the pancreas.
JDRF-funded researchers led by Dr. Pedro Herrera at the University of Geneva in Switzerland have shown that what are called "alpha cells" in the pancreas - specialized cells that do not produce insulin - can spontaneously convert into insulin-producing beta cells. And while these changes took place under very specific experimental conditions in mice, the study advances the prospect of regenerating beta cells as a cure for type 1 diabetes. It points to the unexpected "plasticity," or potential, of pancreas cells to adapt and produce insulin when they must - in this case, when the beta cells that normally produce insulin in those mice were entirely killed off. Ultimately, scientists may be able to harness this conversion potential to regenerate beta cells in people with diabetes.
For the experiments, the researchers used mice in which nearly all of the beta cells are rapidly destroyed. They made two important discoveries - first, that beta cells will spontaneously regenerate after near-total beta cell destruction, and second, that most of these regenerated beta cells come from alpha cells that reprogrammed, or converted, into beta cells. Alpha cells normally reside alongside beta cells in the pancreas and secrete a hormone called glucagon, which works to oppose insulin in regulating levels of sugar in the blood. Alpha cells are not attacked by the autoimmune processes that destroy beta cells and cause type 1 diabetes.
In the experiments, the insulin-producing beta cells were slowly and spontaneously restored, eventually eliminating the mice's need for insulin replacement.
According to Andrew Rakeman, JDRF Program Manager in Beta Cell Therapies, the big breakthrough in Dr. Herrera's work is showing that alpha-to beta-cell reprogramming can be a natural, spontaneous process.
"If we can understand the signals that are triggering this conversion, it will open a whole new potential strategy for regenerating beta cells in people with type 1 diabetes," he said. "It appears now that the body can restore beta cell function either through reprogramming alpha cells to become beta cells or, as has previously been shown by other researchers, by increasing the growth of existing beta cells. This new path may be particularly useful in people who have had diabetes for a long time and have no, or very few, remaining beta cells."
Dr. Herrera's team genetically engineered the mice to be susceptible to a toxin that would destroy only their beta cells. When the mice were exposed to the toxin, the beta cells were rapidly and efficiently destroyed - greater than 99% just 15 days after treatment. To then track the source of newly regenerated beta cells, the researchers used another genetic manipulation to label mature alpha cells (and their descendents) with a fluorescent protein. This "genetic lineage tracing" approach allowed the scientists to track the fate of the alpha cells and their progeny. The presence of fluorescently labeled beta cells in the mice that recovered insulin production was conclusive evidence that alpha cells had reprogrammed into beta cells.
The Geneva researchers pointed out that the critical factor in sparking the alpha-to beta-cell reprogramming was removing nearly all the original insulin-producing cells in the mice. In mice whose loss of beta cells was more modest, the researchers found no evidence of regeneration, and less alpha cell reprogramming. "The amount of beta-cell destruction appears to determine whether regeneration occurs. It influences the degree of cell plasticity and regenerative resources of the pancreas," they explained.
Also noteworthy is that Dr. Herrera's results are the first to show that beta cell reprogramming can occur spontaneously, without genetic manipulation. Previous efforts to reprogram non-beta cells into beta cells relied on altering genes - processes that can not be easily translated into therapies for people.
Key Point: Diabetes researchers have shown that some cells in the pancreas that don't normally produce insulin hold the potential to convert into cells that do. The finding underscores the potential of regeneration as a pathway to achieve normal blood sugar in people with type 1 diabetes.
We tend to regard the mature cells in our bodies as having reached their final destinations - if they become specialists, like heart or brain cells, they remain that way. But more and more, research is showing this is not always the case. And fortunately for people with type 1 diabetes, today's online issue of the journal Nature reports on similar transformational prospects for cells in the pancreas.
JDRF-funded researchers led by Dr. Pedro Herrera at the University of Geneva in Switzerland have shown that what are called "alpha cells" in the pancreas - specialized cells that do not produce insulin - can spontaneously convert into insulin-producing beta cells. And while these changes took place under very specific experimental conditions in mice, the study advances the prospect of regenerating beta cells as a cure for type 1 diabetes. It points to the unexpected "plasticity," or potential, of pancreas cells to adapt and produce insulin when they must - in this case, when the beta cells that normally produce insulin in those mice were entirely killed off. Ultimately, scientists may be able to harness this conversion potential to regenerate beta cells in people with diabetes.
For the experiments, the researchers used mice in which nearly all of the beta cells are rapidly destroyed. They made two important discoveries - first, that beta cells will spontaneously regenerate after near-total beta cell destruction, and second, that most of these regenerated beta cells come from alpha cells that reprogrammed, or converted, into beta cells. Alpha cells normally reside alongside beta cells in the pancreas and secrete a hormone called glucagon, which works to oppose insulin in regulating levels of sugar in the blood. Alpha cells are not attacked by the autoimmune processes that destroy beta cells and cause type 1 diabetes.
In the experiments, the insulin-producing beta cells were slowly and spontaneously restored, eventually eliminating the mice's need for insulin replacement.
According to Andrew Rakeman, JDRF Program Manager in Beta Cell Therapies, the big breakthrough in Dr. Herrera's work is showing that alpha-to beta-cell reprogramming can be a natural, spontaneous process.
"If we can understand the signals that are triggering this conversion, it will open a whole new potential strategy for regenerating beta cells in people with type 1 diabetes," he said. "It appears now that the body can restore beta cell function either through reprogramming alpha cells to become beta cells or, as has previously been shown by other researchers, by increasing the growth of existing beta cells. This new path may be particularly useful in people who have had diabetes for a long time and have no, or very few, remaining beta cells."
Dr. Herrera's team genetically engineered the mice to be susceptible to a toxin that would destroy only their beta cells. When the mice were exposed to the toxin, the beta cells were rapidly and efficiently destroyed - greater than 99% just 15 days after treatment. To then track the source of newly regenerated beta cells, the researchers used another genetic manipulation to label mature alpha cells (and their descendents) with a fluorescent protein. This "genetic lineage tracing" approach allowed the scientists to track the fate of the alpha cells and their progeny. The presence of fluorescently labeled beta cells in the mice that recovered insulin production was conclusive evidence that alpha cells had reprogrammed into beta cells.
The Geneva researchers pointed out that the critical factor in sparking the alpha-to beta-cell reprogramming was removing nearly all the original insulin-producing cells in the mice. In mice whose loss of beta cells was more modest, the researchers found no evidence of regeneration, and less alpha cell reprogramming. "The amount of beta-cell destruction appears to determine whether regeneration occurs. It influences the degree of cell plasticity and regenerative resources of the pancreas," they explained.
Also noteworthy is that Dr. Herrera's results are the first to show that beta cell reprogramming can occur spontaneously, without genetic manipulation. Previous efforts to reprogram non-beta cells into beta cells relied on altering genes - processes that can not be easily translated into therapies for people.
Key Point: Diabetes researchers have shown that some cells in the pancreas that don't normally produce insulin hold the potential to convert into cells that do. The finding underscores the potential of regeneration as a pathway to achieve normal blood sugar in people with type 1 diabetes.
JUST RELEASED ON APRIL 8, 2010.....we are on the edge...
Researchers Use Nanoparticle "Vaccine" to Cure Type 1 Diabetes in Mice
Using an innovative nanotechnology-based "vaccine," researchers were able to successfully restore normal blood sugar in mice with type 1 diabetes, and also slow the onset of diabetes in mice at risk for the disease. The study, co-funded by JDRF and published today in the online edition of the journal Immunity, has several key implications:
First, it provides important new insights into how to stop the immune attack that causes type 1 diabetes.
Second, it underscores the potential of "antigen-specific" therapies. Because the nanoparticle vaccine was designed with specific immune system proteins, it effectively blunted the targeted autoimmune response that causes diabetes without compromising the overall immune system - an issue that continues to be a challenge in developing treatments for diabetes.
And third, it suggests that antigen-specific nanovaccines, because of the effectiveness shown here, might also be developed to treat other autoimmune diseases, such as multiple sclerosis and rheumatoid arthritis. That could make the science more attractive to drug development companies.
Researchers from the University of Calgary in Alberta, led by Dr. Pere Santamaria, were looking to halt the autoimmune response that causes type 1 diabetes, but do so without damaging the immune cells that control and regulate the immune system or that protect against infections. So the team focused on developing a highly targeted antigen-specific immunotherapy - one, they explained, that could address the "internal tug-of-war between aggressive T cells that want to cause the disease and weaker T cells that want to stop it from occurring."
The researchers produced a unique vaccine comprising nanoparticles, which are thousands of times smaller than the size of a cell. They coated the particles with type 1 diabetes-relevant peptides, or protein fragments, that were bound to certain molecules that play a critical role in immune cell communication (called MHC molecules).
In the mice, the nanoparticle treatment expanded a type of regulatory T cell -- these cells ultimately suppressed the aggressive immune attack that destroys the insulin-producing beta cells of the pancreas. The researchers noted that the expanded cells shut down the immune attack by preventing autoreactive immune cells from being stimulated, either by the peptide contained in the vaccine or by any other diabetes autoantigen presented simultaneously by antigen-presenting cells. With the immune response that causes diabetes blocked, mice with type 1 diabetes regained normal blood sugars. And those that would have contracted the disease didn't.
The study also provides important - and promising - insight into the ability to translate these findings into therapeutics for people: Nanoparticles that were coated with molecules specific to human type 1 diabetes were able to restore normal blood sugar levels in a humanized mouse model of diabetes (that is, a mouse that has been genetically altered to biologically simulate type 1 diabetes in people).
According to Teodora Staeva, Ph.D., JDRF Program Director of Immune Therapies, a key finding from the Alberta study is that only the immune cells that specifically focus on aggressively destroying beta cells (or on regulating these aggressive cells) actually responded to the vaccine therapy. That means the treatment did not compromise the rest of the immune system - a key consideration if the treatment is to be safe and effective in an otherwise healthy person with type 1 diabetes. "The potential that nanoparticle vaccine therapy holds in reversing the immune attack without generally suppressing the immune system is significant," said Staeva. "Dr. Santamaria's research has provided both insight into pathways for developing new immunotherapies as well as proof-of-concept of a specific therapy that exploits these pathways for preventing and reversing type 1 diabetes."
The nanoparticle vaccine technology developed by Dr. Santamaria and used in the study has been licensed by Parvus Therapeutics, Inc., a biotechnology company spun out from the University Technology International LP, the technology transfer and commercialization center for the University of Calgary. Parvus is focused on the development and commercialization of a nanotechnology-based therapeutic platform for the treatment of type 1 diabetes.
Using an innovative nanotechnology-based "vaccine," researchers were able to successfully restore normal blood sugar in mice with type 1 diabetes, and also slow the onset of diabetes in mice at risk for the disease. The study, co-funded by JDRF and published today in the online edition of the journal Immunity, has several key implications:
First, it provides important new insights into how to stop the immune attack that causes type 1 diabetes.
Second, it underscores the potential of "antigen-specific" therapies. Because the nanoparticle vaccine was designed with specific immune system proteins, it effectively blunted the targeted autoimmune response that causes diabetes without compromising the overall immune system - an issue that continues to be a challenge in developing treatments for diabetes.
And third, it suggests that antigen-specific nanovaccines, because of the effectiveness shown here, might also be developed to treat other autoimmune diseases, such as multiple sclerosis and rheumatoid arthritis. That could make the science more attractive to drug development companies.
Researchers from the University of Calgary in Alberta, led by Dr. Pere Santamaria, were looking to halt the autoimmune response that causes type 1 diabetes, but do so without damaging the immune cells that control and regulate the immune system or that protect against infections. So the team focused on developing a highly targeted antigen-specific immunotherapy - one, they explained, that could address the "internal tug-of-war between aggressive T cells that want to cause the disease and weaker T cells that want to stop it from occurring."
The researchers produced a unique vaccine comprising nanoparticles, which are thousands of times smaller than the size of a cell. They coated the particles with type 1 diabetes-relevant peptides, or protein fragments, that were bound to certain molecules that play a critical role in immune cell communication (called MHC molecules).
In the mice, the nanoparticle treatment expanded a type of regulatory T cell -- these cells ultimately suppressed the aggressive immune attack that destroys the insulin-producing beta cells of the pancreas. The researchers noted that the expanded cells shut down the immune attack by preventing autoreactive immune cells from being stimulated, either by the peptide contained in the vaccine or by any other diabetes autoantigen presented simultaneously by antigen-presenting cells. With the immune response that causes diabetes blocked, mice with type 1 diabetes regained normal blood sugars. And those that would have contracted the disease didn't.
The study also provides important - and promising - insight into the ability to translate these findings into therapeutics for people: Nanoparticles that were coated with molecules specific to human type 1 diabetes were able to restore normal blood sugar levels in a humanized mouse model of diabetes (that is, a mouse that has been genetically altered to biologically simulate type 1 diabetes in people).
According to Teodora Staeva, Ph.D., JDRF Program Director of Immune Therapies, a key finding from the Alberta study is that only the immune cells that specifically focus on aggressively destroying beta cells (or on regulating these aggressive cells) actually responded to the vaccine therapy. That means the treatment did not compromise the rest of the immune system - a key consideration if the treatment is to be safe and effective in an otherwise healthy person with type 1 diabetes. "The potential that nanoparticle vaccine therapy holds in reversing the immune attack without generally suppressing the immune system is significant," said Staeva. "Dr. Santamaria's research has provided both insight into pathways for developing new immunotherapies as well as proof-of-concept of a specific therapy that exploits these pathways for preventing and reversing type 1 diabetes."
The nanoparticle vaccine technology developed by Dr. Santamaria and used in the study has been licensed by Parvus Therapeutics, Inc., a biotechnology company spun out from the University Technology International LP, the technology transfer and commercialization center for the University of Calgary. Parvus is focused on the development and commercialization of a nanotechnology-based therapeutic platform for the treatment of type 1 diabetes.
Monday, April 12, 2010
Connecticut Expo Center Map & Directions.
Map & Directions
The Connecticut Expo Center is one of the most accessible exhibition halls not only in the Northeast, but in all the country: We’re just seconds off Exit 33 of Interstate-91 and mere minutes from Downtown Hartford, the city’s Amtrak station and Bradley International Airport. And, of course, Hartford is halfway between Boston and New York and is an easy drive from both cities.
So if you’re planning to attend—or exhibit—at one of our shows, you’ll find that the Connecticut Expo Center is exceptionally easy to get to—and we have plenty of parking adjacent to our facility!
From Points East and West of Hartford:
I-84 to I-91 North. Exit 33 (Jennings Road). At the end of the ramp, take a left. At the second light, take a left onto Weston Street. At the second light, take a right onto New Road. The entrance to the Connecticut Expo Center will be on your left.
From Points South of Hartford:
I-91 North to Exit 33 (Jennings Road). At the end of the ramp, take a left. At the second light, take a left onto Weston Street. At the second light, take a right onto New Road. The entrance to the Connecticut Expo Center will be on your left.
From Point North of Hartford:
I-91 South to Exit 33 (Jennings Road). At the end of the ramp, take a right. At the first light, take a left onto Weston Street. At the second light, take a right onto New Road. The entrance to the Connecticut Expo Center will be on your left.
Click Here for an interactive map
The Connecticut Expo Center is one of the most accessible exhibition halls not only in the Northeast, but in all the country: We’re just seconds off Exit 33 of Interstate-91 and mere minutes from Downtown Hartford, the city’s Amtrak station and Bradley International Airport. And, of course, Hartford is halfway between Boston and New York and is an easy drive from both cities.
So if you’re planning to attend—or exhibit—at one of our shows, you’ll find that the Connecticut Expo Center is exceptionally easy to get to—and we have plenty of parking adjacent to our facility!
From Points East and West of Hartford:
I-84 to I-91 North. Exit 33 (Jennings Road). At the end of the ramp, take a left. At the second light, take a left onto Weston Street. At the second light, take a right onto New Road. The entrance to the Connecticut Expo Center will be on your left.
From Points South of Hartford:
I-91 North to Exit 33 (Jennings Road). At the end of the ramp, take a left. At the second light, take a left onto Weston Street. At the second light, take a right onto New Road. The entrance to the Connecticut Expo Center will be on your left.
From Point North of Hartford:
I-91 South to Exit 33 (Jennings Road). At the end of the ramp, take a right. At the first light, take a left onto Weston Street. At the second light, take a right onto New Road. The entrance to the Connecticut Expo Center will be on your left.
Click Here for an interactive map
Diabetes convention at the Hartford, Ct. Civic Center.
The Tummietote by Tallygear will be shown and available at the vendor fair on Saturdat April 17, 2010 from 10 am to 2 p.m.at the Hartford Civic Center. There are going to be alot of great things going on there. Please stop by there are usually more than 3500 attendees.
Below is some information on the fair ...time, location, info, link below with address to get there....
Featured Event
Event: ADA Diabetes Expo
Date: Saturday, April 17, 2010
Date: April 17, 2010
Time: 10:00 AM - 3:00 PM
Contact: Louise Butcher, 860-639-0385 860-639-0385 x3532
or lbutcher@diabetes.org
The EXPO is FREE and includes health screenings, cooking demonstrations, product and service exhibitors, as well as leading experts talking about diabetes management and prevention. Get the latest information on preventing and managing diabetes and its deadly complications to help keep you and your family healthy.
Visit the American Diabetes Association EXPO/Hartford and join the movement to Stop Diabetes™. Learn how to live healthy, be active, and change the future of diabetes for you and your family.
more information and pre-registration:
http://main.diabetes.org/site/Calendar/130535562?view=Detail&id=9101
Below is some information on the fair ...time, location, info, link below with address to get there....
Featured Event
Event: ADA Diabetes Expo
Date: Saturday, April 17, 2010
Date: April 17, 2010
Time: 10:00 AM - 3:00 PM
Contact: Louise Butcher, 860-639-0385 860-639-0385 x3532
or lbutcher@diabetes.org
The EXPO is FREE and includes health screenings, cooking demonstrations, product and service exhibitors, as well as leading experts talking about diabetes management and prevention. Get the latest information on preventing and managing diabetes and its deadly complications to help keep you and your family healthy.
Visit the American Diabetes Association EXPO/Hartford and join the movement to Stop Diabetes™. Learn how to live healthy, be active, and change the future of diabetes for you and your family.
more information and pre-registration:
American Diabetes Tour De Cure.....
Welcome
Tour de Cure is a series of fundraising cycling events held in 43 states nationwide to benefit the American Diabetes Association.
The Tour is a ride, not a race, with routes designed for everyone from the occasional rider to the experienced cyclist. Whether participants ride 10 miles or 100 miles*, they will travel a route supported from start to finish with rest stops, food to fuel the journey and fans to cheer them on!
Last year, more than 40,000 cyclists in 80 Tour events raised nearly $17 million to support the mission of the ADA: to prevent and cure diabetes and to improve the lives of all people affected by diabetes.
Take the Ride of Your Life. Sign up today.
Register or Request More Information online, or by calling your local American Diabetes Association office at 1-888-DIABETES.
*Ride route distances vary from event to event.
You are why we ride!
A Red Rider is someone living with diabetes (type 1 or type 2) who rides in the Tour de Cure as an individual or on a team! Learn more about how you can be recognized as a RED RIDER!
Tour de Cure is a series of fundraising cycling events held in 43 states nationwide to benefit the American Diabetes Association.
The Tour is a ride, not a race, with routes designed for everyone from the occasional rider to the experienced cyclist. Whether participants ride 10 miles or 100 miles*, they will travel a route supported from start to finish with rest stops, food to fuel the journey and fans to cheer them on!
Last year, more than 40,000 cyclists in 80 Tour events raised nearly $17 million to support the mission of the ADA: to prevent and cure diabetes and to improve the lives of all people affected by diabetes.
Take the Ride of Your Life. Sign up today.
Register or Request More Information online, or by calling your local American Diabetes Association office at 1-888-DIABETES.
*Ride route distances vary from event to event.
You are why we ride!
A Red Rider is someone living with diabetes (type 1 or type 2) who rides in the Tour de Cure as an individual or on a team! Learn more about how you can be recognized as a RED RIDER!
TOUR DE CURE.....go Team Tally!!!!.....
My sister is riding in this National Juvenile Diabetes event.....AWESOME!!!!!
GO TEAM TALLY!!!!!
Tour De Cure
This is an email I received from her today, if anyone is looking for specifics!.....
OK - so I have heard back that some of you are interested in joining
me for the 'Tour De Cure' (www.tour.diabetes.org) - I have registered
for the New England Classic 150 and formed "Team Tally" so if you sign
up be sure to join my team. They will give you a fundraising page
where people can contribute online - makes it much easier. And we can
all ride together.. Please forward this to anyone else that you think
may be interested in joining our team....
We will be riding for my sweet adorable niece Tallia Emily who has
type 1 diabetes as well as any friends and family members that you
would like to add to the list.
The ride that I am doing is July 10-11 and 75 miles each day (total
150). It is a supported ride (includes support and gear
transportation, mechanical assistance, medical volunteers,police
escorts, directional signs, rest stops every 10-12 miles with food and
drink and lodging at UNH) and requires a $600 min fundraising amount.
If you register now its $50 - but goes up to $80.
The ride begins in Woburn MA Saturday morning and goes to UNH the
first day where we stay overnight. The second days ride begins in
Durham NH and goes to Biddeford Maine. The ride continues from here
for the 550 miler (5 days). The participants of the 2 day ride are
driven back to Woburn.
If you register for the Classic, you can ride other New England Tour
de Cure rides for training without raising additional funds. Contact
the ride office to register. Other ride dates are:
Gloucester, MA - May 22, 2010
Narragansett, RI - June 6, 2010
North Haven, CT - June 12, 2010
Kennebunk, ME - June 13, 2010
Tour de Cure is a series of fundraising cycling events held in 43
states nationwide to benefit the American Diabetes Association.
The Tour is a ride, not a race, with routes designed for everyone from
the occasional rider to the experienced cyclist. Whether participants
ride 10 miles or 100 miles*, they will travel a route supported from
start to finish with rest stops, food to fuel the journey and fans to
cheer them on!
http://tour.diabetes.org/
Lynne will also be riding with the Tallygear Tummietote on.....
GO TEAM TALLY!!!!!
Tour De Cure
This is an email I received from her today, if anyone is looking for specifics!.....
OK - so I have heard back that some of you are interested in joining
me for the 'Tour De Cure' (www.tour.diabetes.org) - I have registered
for the New England Classic 150 and formed "Team Tally" so if you sign
up be sure to join my team. They will give you a fundraising page
where people can contribute online - makes it much easier. And we can
all ride together.. Please forward this to anyone else that you think
may be interested in joining our team....
We will be riding for my sweet adorable niece Tallia Emily who has
type 1 diabetes as well as any friends and family members that you
would like to add to the list.
The ride that I am doing is July 10-11 and 75 miles each day (total
150). It is a supported ride (includes support and gear
transportation, mechanical assistance, medical volunteers,police
escorts, directional signs, rest stops every 10-12 miles with food and
drink and lodging at UNH) and requires a $600 min fundraising amount.
If you register now its $50 - but goes up to $80.
The ride begins in Woburn MA Saturday morning and goes to UNH the
first day where we stay overnight. The second days ride begins in
Durham NH and goes to Biddeford Maine. The ride continues from here
for the 550 miler (5 days). The participants of the 2 day ride are
driven back to Woburn.
If you register for the Classic, you can ride other New England Tour
de Cure rides for training without raising additional funds. Contact
the ride office to register. Other ride dates are:
Gloucester, MA - May 22, 2010
Narragansett, RI - June 6, 2010
North Haven, CT - June 12, 2010
Kennebunk, ME - June 13, 2010
Tour de Cure is a series of fundraising cycling events held in 43
states nationwide to benefit the American Diabetes Association.
The Tour is a ride, not a race, with routes designed for everyone from
the occasional rider to the experienced cyclist. Whether participants
ride 10 miles or 100 miles*, they will travel a route supported from
start to finish with rest stops, food to fuel the journey and fans to
cheer them on!
http://tour.diabetes.org/
Lynne will also be riding with the Tallygear Tummietote on.....
Wednesday, April 7, 2010
Tuesday, April 6, 2010
TUMMIETOTE by TALLYGEAR new site almost complete......
www.tallygear.com will have a new look soon, we went green and used fatcow to design the new tallyygear site. their stuff is powered by wind, a renewable resource and that makes us feel good. please stay tuned for the new look.....
Thursday, April 1, 2010
Subscribe to:
Posts (Atom)